The world map shows the countries and regions for which master data analyses for SARS-CoV-2 are available. The darker the red, the more data is available. The data comes from GISAID and the WHO. Since ...

During the first few years of the COVID-19 pandemic, the virus SARS-CoV-2 was detected in an increasing number of non-human ...

Invivyd, Inc. has announced new in vitro data showing that its monoclonal antibody PEMGARDA™ (pemivibart) maintains effective neutralizing activity against the prevalent LP.8.1 variant of SARS-CoV-2, ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the original wild-type strains to the highly transmissible Omicron variant.

CoVFit can predict the epidemic potential—i.e., the fitness—of SARS-CoV-2 variants based solely on their spike protein sequences. Viral infectious diseases pose significant challenges due to the rapid ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...

In a new study, researchers at Yale University performed surveillance to understand the current coronaviral landscape of wild and domestic animals in the northeastern United States. They found that ...

PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1 and XEC. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD ...

UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...

In a large, population-based cohort, previously healthy children and adolescents who experienced acute SARS-CoV-2 infection had more than twice the risk of developing type 1 diabetes (T1D) within 6 ...